Evidence map›Paper›PMID 41031251›Full record

ArticleBioMed research international2025

Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance.

Fatemeh Nasiri Kenari, Masoumeh Saberian, Matthew Abikenari, Safa Najafi, Majid Sadeghizadeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fatemeh Nasiri KenariDepartment of Molecular Genetics, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran, modares.ac.ir.ORCID https://orcid.org/0009-0004-1335-143X
Masoumeh SaberianDepartment of Hematology and Oncology, Valiasr Hospital, Tehran, Iran.ORCID https://orcid.org/0000-0002-9295-0454
Matthew AbikenariDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA, stanford.edu.ORCID https://orcid.org/0000-0001-5835-5179
Safa NajafiDepartment of Oncology, Motamed Cancer Institute, Tehran, Iran.ORCID https://orcid.org/0000-0002-1376-2798
Majid SadeghizadehDepartment of Molecular Genetics, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran, modares.ac.ir.ORCID https://orcid.org/0000-0002-2497-3152

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsCurcuminDrug Resistance, NeoplasmRNA, Long NoncodingTamoxifenCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsMiddle AgedNanoparticlesCurcuminMALAT1 long non-coding RNA, humannanocurcuminRNA, Long NoncodingTamoxifenbreast cancerlncRNA MALAT1NanoCurcuminplasma biomarkertamoxifen resistance

Identifiers

PMID41031251
PMCPMC12407302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.